Suppression of growth of H-69 small cell lung carcinoma by antagonists of growth hormone releasing hormone and bombesin is associated with an inhibition of protein kinase C signaling

International Journal of Cancer

Volumn 112, Issue 4, 2004, Pages 570-576

  Kanashiro, Celia A ^a,b   Schally, Andrew V ^a,b   Zarandi, Marta ^a,b   Hammann, Brian D ^a,b   Varga, Jozsef L ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bombesin GRP antagonist; Cancer therapy; GHRH antagonists; Protein kinase C

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; BISINDOLYLMALEIMIDE; BOMBESIN ANTAGONIST; BOMBESIN RECEPTOR; GASTRIN RELEASING PEPTIDE; GASTRIN RELEASING PEPTIDE DERIVATIVE; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE RELEASING FACTOR RECEPTOR; HORMONE ANTAGONIST; ISOENZYME; JV 1 65; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MZ J 7 110; PROTEIN KINASE C; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; PROTEIN KINASE C DELTA; PROTEIN KINASE C INHIBITOR; RC 3940 II; RECEPTOR PROTEIN; SERMORELIN; SERMORELIN[1 PHENYLACETYLTYROSINE 2 DEXTRO ARGININE 6 (4 CHLOROPHENYLALANINE) 9 (4 AMIDINOPHENYLALANINE) 10 METHYLTYROSINE 15 ALPHA AMINOBUTYRIC ACID 27 NORLEUCINE 28 DEXTRO ARGININE 29 HOMOARGININE]; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; NUDE MOUSE; ONCOGENE C FOS; ONCOGENE C JUN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN VARIANT; RECEPTOR BLOCKING; RNA ANALYSIS; SIGNAL TRANSDUCTION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; BOMBESIN; CARCINOMA, SMALL CELL; CELL DIVISION; GROWTH HORMONE-RELEASING HORMONE; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PROTEIN KINASE C; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 7044235571     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20437     Document Type: Article

References (55)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer Statistics. CA Cancer J Clin 2002;52:23-47.
2. Colby TV, Koss MN, Travis WD. Tumors of the lower respiratory tract, 3rd series, Fascicle 13. Washington, DC: Armed Forces Institute of Pathology, 1995. 1-554.
3. Siegfried JM, DeMichele MA, Hunt JD, Davis AG, Yohra KP, Pilewski JM. Expression of mRNA for gastrin-releasing peptide receptor by human bronchial epithelial cells: association with prolonged tobacco exposure and responsiveness to bombesin-like peptide. Am J Respir Crit Care Med 1997;156:358-66.
4. Sunday ME, Hua J, Dai HB, Nusrul A, Torday JS. Bombesin increases fetal lung growth and maturation in utero and in organ culture. Am J Respir Cell Mol Biol 1990;3:199-205.
5. Sunday ME, Hua J, Torday JS, Reyes B, Shipp MA. CD10/neutral endopeptidase 24.11 in development human fetal lung. Patterns of expression and modulation of peptide-mediated proliferation. J Clin Invest 1992;90:2517-25.
6. Spindel ER. Roles of bombesin-like peptides in lung development and lung injury. Am J Respir Cell Mol Biol 1996;14:407-8.
7. Cuttita F, Carney DN, Mulshine J, Moody TW, Fedorko J, Fischler A, Minna JD. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature 1985;316:823-6.
8. Kiaris H, Schally AV, Nagy A, Sun B, Armatis P, Szepeshazi K. Targeted cytotoxic analog of bombesin/gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice. Br J Cancer 1999;81:966-71.
9. Spindel ER, Giladi E, Segerson TP, Nagalla S. Bombesin-like peptides: of ligands and receptors. Rec Progr Horm Res 1993;48:365-91.
10. Schally AV, Comaru-Schally AM, Nagy A, Kovacs M, Szepeshazi K, Plonowski A, Varga JL, Halmos G. Hypothalamic hormones and cancer. Front Neuroendocrinol 2001;22:248-91.
11. Fathi Z, Way JW, Corjay MH, Viallet J, Sausville EA, Battey JF. Bombesin receptor structure and expression in human lung carcinoma cell lines. J Cell Biochem Suppl 1996;24:237-46.
12. Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K, O'Byrne K, Cai R-Z. Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice. Br J Cancer 1994;70:886-92.
13. Koppan M, Halmos G, Arencibia JM, Lamharzi N, Schally AV. Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma. Cancer 1998;83:1335-43.
14. Rozengurt E. Bombesin stimulation of mitogenesis: specific receptors, signal transduction, and early events. Am Rev Respir Dis 1990;142:S11-15.
15. Schally AV, Varga JL. Antagonistic analogs of growth hormone-releasing hormone: new potential antitumor agents. Trends Endocrinol Metab 1999;10:383-91.
16. Pinski J, Schally AV, Jungwirth A, Groot K, Halmos G, Armatis P, Zarandi M, Vadillo-Buenfil M. Inhibition of growth of human small-cell and non-small cell lung carcinomas by antagonists of growth hormone-releasing hormone (GH-RH). Int J Oncol 1996;9:1099-105.
17. Kiaris H, Schally AV, Varga JL, Groot K, Armatis P. Growth hormone-releasing hormone: An autocrine growth factor for small cell lung carcinoma. Proc Natl Acad Sci U S A 1999;96:14894-8.
18. Rekasi Z, Czompoly T, Schally AV, Halmos G. Isolation and sequencing of cDNAS for splice variants of growth hormone-releasing hormone receptors from human cancers. Proc Natl Acad Sci U S A 2000;97:10561-6.
19. Halmos G, Schally AV, Varga JL, Plonowski A, Rekasi Z, Czompoly T. Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone. Proc Natl Acad Sci U S A 2000;97:10555-60.
20. Kiaris H, Schally AV, Busto R, Halmos G, Artavanis-Tsakonas S, Varga JL. Expression of a splice variant of the receptor for GHRH in 3T3 fibroblasts activates cell proliferation responses to GHRH analogs. Proc Natl Acad Sci U S A 2002;99:196-200.
21. Wu D, Clark IJ, Chen C. The role of PKC in GH secretion induced by GH-releasing factor and GH-releasing peptides in cultured ovine somatotropes. J Endocrinol 1997;154:219-30.
22. Kanashiro CA, Khalil RA. Signal transduction by protein kinase C in mammalian cells. Clin Exp Pharmacol Physiol 1998;25:974-85.
23. Carter CA. Protein kinase C as a drug target: implications for drug or diet prevention and treatment of cancer. Curr Drug Targets 2000;1:163-83.
24. Bajo AM, Schally AV, Krupa M, Hebert F, Groot K, Szepeshazi K. Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the Erb-B/HER-2 oncoprotein and c-jun and c-fos oncogenes. Proc Natl Acad Sci U S A 2002;99:3836-41.
25. Campbell, JS, Seger R, Graves JD, Graves LM, Jensen AM, Krebs EG. The MAPK kinase cascade. Recent Prog Horm Res 1995;50:131-59.
26. Cook SJ, Rubinfeld B, Albert I, McCornick F. RapV12 antagonizes Ras-dependent activation of ERK1 and Erk2 by LPA and EGF in Rat-1 fibroblasts. EMBO J 1993;12:3475-85.
27. Pajes G, Lenormand P, L'Allemain G, Chambard J, Meloche S, Pousségur J. Mitogen-activated protein kinase p42 MAPK and p44 MAPK are required for fibroblast proliferation. Proc Natl Acad Sci U S A 1993;90:8319-23.
28. Lee EJ, Duan WR, Kotlar T, Jameson L. Restoration of growth hormone-releasing hormone (GHRH) responsiveness in pituitary GH3 cells by adenovirus-directed expression of the human GHRH receptor. Endocrinology 2001;142:414-20.
29. Schally AV, Comaru-Schally AM. Hypothalamic and other peptide hormones. In: Bast RC, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei III E. Cancer medicine, 6th ed. Lewiston, NY: Decker, 2003, 911-26.
30. 2. Int J Oncol 1995;7:749-54.
31. Varga JL, Schally AV, Horvarth JE, Kovacs M, Halmos G, Groot K, Toller GL, Rekasi Z, Zarandi M. Increased activity of antagonists of growth hormone-releasing hormone substituted at positions 8, 9 and 10. Proc Natl Acad Sci U S A 2004;101:1708-13.
32. Smolev JK, Heston WDW, Scott WW, Coffey DS. Characterization of the Dunning R3327H prostatic adenocarcinoma: an appropriate animal model for prostate cancer. Cancer Treat Rep 1997;61:273-87.
33. Kanashiro CA, Khalil RA. Gender-related distinctions in protein kinase C activity in rat vascular smooth muscle. Am J Physiol 2001;280:34-45.
34. Plumb JA, Milroy R, Kaye SB. Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-y1)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res 1989;49:4435-40.
35. Plonowski A, Schally AV, Varga JL, Rekasi Z, Hebert F, Halmos G, Groot K. Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways. The Prostate 2000;44:172-80.
36. Kanashiro CA, Schally AV, Groot K, Armatis P, Bernardino ALF, Varga, JL. Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin. Proc Natl Acad Sci U S A 2003;100:15836-841.
37. Halmos G, Schally AV. Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095. Proc Natl Acad Sci U S A 1997;94:956-60.
38. Ramirez JL, Castano JP, Torronteras R, Martinez-Fuentes AJ, Frawley LS, Garcia-Navarro S, Gracia-Navarro F. GH-releasing factor differentially activates cAMP and inositol phosphate-dependent pathways to stimulate GH release in two porcine somatotrope subpopulations. Endocrinology 1999;140:1752-59.
39. Gaylinn BD. Molecular and cell biology of the growth hormone-releasing hormone receptor. Growth Horm IGF Res 1999;9:37-44.
40. Hirai M, Gamous S, Kobayashi M, Shimizu N. Lung cancer cells often express high levels of protein kinase C activity. Jpn J Cancer Res 1989;80:204-8
41. Fabbro D, Ruetz S, Bodis S, Pruschy M, Man A, Campochiaro P, Wood J, O'Reilly T, Meyer T. PKC412 a protein kinase inhibitor with a broad therapeutical potential. Anti-Cancer Drug Design 2000;15:17-28.
42. Grosios K. UCN-01 Kyowa Hakko Kogyo Co. Curr Opinion Invest Drugs 2001;2:287-97.
43. Swannie HC, Kaye SB. Protein kinase C inhibitors. Curr Oncol Rep 2002;4:37-46.
44. Mani S, Rudin CM, Kunkel K, Holmlund JT, Geary RS, Kindler HL, Dorr FA, Ratain MJ. Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. Clin Cancer Res 2002;8:1042-8.
45. Teicher BA, Alvarez E, Menselsohn LG, Ara G, Menon K, Ways DK. Enzymatic rationale and preclinical support for a potent protein kinase C beta inhibitor in cancer therapy. Adv Enzyme Regul 1999;39:313-27.
46. La Porta CA, Tessitore L, Comolli R. Changes in protein kinase C alpha, delta and in nuclear beta isoform expression in tumor and lung metastatic nodules induced by diethylnitrosamine in the rat. Carcinogenesis 1997;18:715-9.
47. Barr LF, Campbell SE, Baylin SB. Protein kinase C-beta 2 inhibits cycling and decreases c-myc-induced apoptosis in small cell lung cancer cells. Cell Growth Diff 1997;8:381-92.
48. Kiley SC, Clark KJ, Goodnough M, Welch DR, Jaken S. Protein kinase C delta involvement in mammary tumor cell metastasis. Cancer Res 1999;9:3230-8.
49. Clark AS, West KA, Blumberg PM, Dennis PA. Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKC delta promotes cellular survival and chemotherapeutic resistance. Cancer Res 2003;3:780-6.
50. Pulverer BJ, Kyriakis JM, Avruch J, Nikolakaki E, Woodgett JR. Phosphorylation of c-jun mediated by MAP-kinase. Nature 1991;53:670-4.
51. Uberall F, Kampfer S, Doppler W, Grunicke HH. Activation of c-fos expression by transforming Ha-ras in HC11 mouse mammary epithelial cells is PKC-dependent and mediated by serum responsive element. Cell Signaling 1994;6:285-97.
52. Fung H, Quinlan TR, Janssen YMW, Timblin CR, Marsh JP, Heintz NH, Tatjes DJ, Vacek P, Jaken S Mossman BT. Inhibition of protein kinase C prevents asbestos-induced c-fos and c-jun proto-oncogenes expression in mesothelial cells. Cancer Res 1997;57:3101-5.
53. Baranes D, Razin E. Protein kinase C regulates proliferation of mast cells and the expression of the mRNAs of fos and jun protooncogenes during activation by IgE-Ag or calcium ionophore A23187. Blood 1991;78:2354-9.
54. Wang H, Mohammad RM, Werdell J, Shekhar PV. p53 and protein kinase C independent induction of growth arrest and apoptosis by bryostatin 1 in a highly metastatic mammary epithelial cell line: in vitro versus in vivo activity. Int J Mol Med 1998;1:915-23.
55. O'Brian CA, Ward NE. Biology of the protein kinase C family. Cancer Metastasis Rev 1989;8:199-214.